Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | THRB | P10828 | 1/20 | 0.30 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL40194 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL22199369 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL19228952 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL19228957 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL19228949 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL10089720 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL10101994 | 1.00 | TSHR (0.40) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL935503 | 0.95 | — | — | |
| SCHEMBL26205670 | 0.90 | TSHR (0.47) | TSHRMEN1KMT2AALDH1A1HSD17B10 | |
| SCHEMBL22589673 | 0.86 | TSHR (0.48) | TSHRMEN1KMT2AALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230339929-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230270868-A1 | PYRROLOBENZODIAZEPINE DIMER PRODRUG AND LIGAND-LINKER CONJUGATE COMPOUND OF THE SAME | LIGACHEM BIOSCIENCES INC. (KR) | 2023-08-31 | — | — | US | disclosed |
| EP-3119761-B1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| WO-2021055639-A1 | METHODS OF DETECTING NEUROLOGICAL DISORDERS VIA BINDING TO PHOSPHORYLATED TAU PROTEIN | SARRAF STELLA (US) | 2021-03-25 | — | — | WO | disclosed |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | PFIZER INC. (US) | 2020-12-01 | — | — | US | disclosed |
| US-20180022865-A1 | CONJUGATED POLYMER CONTAINING ETHYNYL CROSSLINKING GROUP, MIXTURE COMPOSITION, ORGANIC ELECTRONIC DEVICE CONTINAING THE SAME AND APPLICATION THEROF | GUANGZHOU CHINARAY OPTOELECTRONIC MATERIALS LTD. (CN) | 2018-01-25 | — | — | US | disclosed |
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | AMGEN INC. | 2017-11-30 | — | — | US | disclosed |
| US-20170137801-A1 | TISSUE-SPECIFIC GENOME ENGINEERING USING CRISPR-CAS9 | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2017-05-18 | — | — | US | disclosed |
| US-9562023-B2 | Dipeptide mimics, libraries combining two dipeptide mimics with a third group, and methods for production thereof | Burgess, Kevin (US) | 2017-02-07 | — | — | US | disclosed |
| US-9550704-B2 | Method for synthesizing radiopharmaceuticals using a cartridge | FUTURECHEM CO., LTD. (KR) | 2017-01-24 | — | — | US | disclosed |
| WO-2015143185-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS (US) | 2015-09-24 | — | — | WO | disclosed |
| US-20150232392-A1 | METHOD FOR SYNTHESIZING RADIOPHARMACEUTICALS USING A CARTRIDGE | FUTURECHEM CO., LTD. (KR) | 2015-08-20 | — | — | US | disclosed |
| US-20150210781-A1 | MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG | NANTES UNIVERSITE (FR) | 2015-07-30 | — | — | US | disclosed |
| US-20150037419-A1 | Functional PLA-PEG Copolymers, the Nanoparticles Thereof, Their Preparation and Use for Targeted Drug Delivery and Imaging | SANOFI (FR) | 2015-02-05 | — | — | US | disclosed |
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | UNIVERSITEIT ANTWERPEN (BE) | 2014-03-20 | — | — | US | disclosed |
| US-20130310912-A1 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES (US) | 2013-11-21 | — | — | US | disclosed |
| US-20120046735-A1 | PLASMA MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES, INCORPORATED (US) | 2012-02-23 | — | — | US | disclosed |
| US-20120046757-A1 | COVALENT MODIFICATION OF METAL SURFACES | INTEZYNE TECHNOLOGIES (US) | 2012-02-23 | — | — | US | disclosed |
| US-8066824-B2 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES, INC. (US) | 2011-11-29 | — | — | US | disclosed |
| US-20080035243-A1 | Covalent modification of metal surfaces | INTEZYNE TECHNOLOGIES (US) | 2008-02-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080035243-A1 | Covalent modification of metal surfaces | ITGAL, ITGA1, ITGA5 | TSHR 3733/4885MEN1 3171/4885KMT2A 1129/4885 |
| US-20150232392-A1 | METHOD FOR SYNTHESIZING RADIOPHARMACEUTICALS USING A CARTRIDGE | ADCYAP1R1, PAICS, SSTR5 | TSHR 71/4885MEN1 5/4885KMT2A 3414/4885 |
| US-20170340746-A1 | PEGYLATED CARFILZOMIB COMPOUNDS | MCL1, FCGRT, MAN2B1 | TSHR 2522/4885MEN1 685/4885KMT2A 745/4885 |
| US-20230339929-A1 | THERAPEUTIC AGENTS AND METHODS OF TREATMENT | SLC10A1, HDGF, NHERF1 | TSHR 1912/4885MEN1 1399/4885KMT2A 4140/4885 |
| US-20120046757-A1 | COVALENT MODIFICATION OF METAL SURFACES | ITGAL, ITGA1, ITGA5 | TSHR 3733/4885MEN1 3171/4885KMT2A 1129/4885 |
| US-10851367-B2 | Tissue-specific genome engineering using CRISPR-Cas9 | ASGR1, LDLR, HAVCR2 | TSHR 823/4885MEN1 4106/4885KMT2A 3195/4885 |
| US-20140079632-A1 | ACTIVITY-BASED PROBES FOR THE UROKINASE PLASMINOGEN ACTIVATOR | PLAU, SERPINE1, PRSS3 | TSHR 1872/4885MEN1 2509/4885KMT2A 4344/4885 |
| US-20150210781-A1 | MULTIMERIC MANNOSIDES, A PROCESS FOR PREPARING THE SAME AND THEIR USES AS A DRUG | MANBA, MAN2A1, MAN2B2 | TSHR 4747/4885MEN1 112/4885KMT2A 3423/4885 |
| US-20230270868-A1 | PYRROLOBENZODIAZEPINE DIMER PRODRUG AND LIGAND-LINKER CONJUGATE COMPOUND OF THE SAME | BCR, PIN1, PAICS | TSHR 1884/4885MEN1 2543/4885KMT2A 1569/4885 |
| US-20150037419-A1 | Functional PLA-PEG Copolymers, the Nanoparticles Thereof, Their Preparation and Use for Targeted Drug Delivery and Imaging | NAPEPLD, LPXN, PCNP | TSHR 4575/4885MEN1 3378/4885KMT2A 4295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.